Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:	18 September 2026
Date of last disclosure:	9 September 2026

Director or senior manager giving disclosure

Full name(s):	Andrew Robert Donald Somervell
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Vice President - Products & Technology

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:	a) Performance Share Rights b) Options to acquire Ordinary Shares c) Ordinary Shares
Nature of the affected relevant interest(s):	Beneficial Interest

For that relevant interest-

Number held in class before acquisition or disposal:	a) 66,418 Performance Share Rights b) 64,269 Options to acquire Ordinary Shares c) 146,624 Ordinary Shares
Number held in class after acquisition or disposal:	a) 50,419 Performance Share Rights b) 27,504 Options to acquire Ordinary Shares c) 155,763 Ordinary Shares
Current registered holder(s):	Andrew Robert Donald Somervell
Registered holder(s) once transfers are registered:	Andrew Robert Donald Somervell

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:	
Class of underlying financial products:	

Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	

For that derivative,-

Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:	Three

Details of transactions requiring disclosure-

Date of transaction:	a) 17 September 2026 b) 15 September 2026 c) 14 September 2026

Nature of transaction:	a) Exercise of Performance Share Rights and Issue of Ordinary Shares b) Exercise and cancellation of Options and Issue of Ordinary Shares c) Sale of Ordinary Shares
Name of any other party or parties to the transaction (if known):	
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	a) Nil b) Exercise price of $21.96 per Ordinary Share c) $43.3297 per Ordinary Share
Number of financial products to which the transaction related:	a) Exercise of 15,999 Performance Share Rights and Issue of 15,999 Ordinary Shares b) Exercise of 36,765 Options and Issue of 18,140 Ordinary Shares c) Sale of 25,000 Ordinary Shares

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period:	
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:	
Nature of relevant interest:	

For that relevant interest,-

Number held in class:	
Current registered holder(s):	

For a derivative relevant interest,-

Type of derivative:	

Details of derivative,-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

Certification

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	

or

Signature of person authorised to sign on behalf of director or officer:	Raelene Leonard
Date of signature:	18 September 2026
Name and title of authorised person:	Raelene Leonard, General Counsel & Company Secretary

NZX

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:	18 September 2026
Date of last disclosure:	9 September 2026

Director or senior manager giving disclosure

Full name(s):	Andrew Grant Niccol
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Chief Operating Officer

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:	a) Options to acquire Ordinary Shares b) Performance Share Rights c) Ordinary Shares
Nature of the affected relevant interest(s):	Beneficial Interest

For that relevant interest-

Number held in class before acquisition or disposal:	a) 18,345 Options to acquire Ordinary Shares b) 30,272 Performance Share Rights c) 2,976 Ordinary Shares
Number held in class after acquisition or disposal:	a) 9,521 Options to acquire Ordinary Shares b) 26,432 Performance Share Rights c) 11,169 Ordinary Shares
Current registered holder(s):	Andrew Grant Niccol
Registered holder(s) once transfers are registered:	Andrew Grant Niccol

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:	
Class of underlying financial products:	

Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	

For that derivative,-

Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:	Two

Details of transactions requiring disclosure-

Date of transaction:	a) 15 September 2026 b) 15 September 2026
Nature of transaction:	a) Exercise and cancellation of Options and Issue of Ordinary Shares b) Exercise of Performance Share Rights and Issue of Ordinary Shares
Name of any other party or parties to the transaction (if known):	
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	a) Exercise price of $21.96 per Ordinary Share b) Nil
Number of financial products to which the transaction related:	a) Exercise of 8,824 Options and Issue of 4,353 Ordinary Shares b) Exercise of 3,840 Performance Share Rights and Issue of 3,840 Ordinary Shares

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period:	
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:	
Nature of relevant interest:	
For that relevant interest,-	
Number held in class:	
Current registered holder(s):	
For a derivative relevant interest,-	
Type of derivative:	

Details of derivative,-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

Certification

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	
or	
Signature of person authorised to sign on behalf of director or officer:	Raelene Leonard
Date of signature:	18 September 2026
Name and title of authorised person:	Raelene Leonard, General Counsel & Company Secretary

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:	18 September 2026
Date of last disclosure:	9 September 2026

Director or senior manager giving disclosure

Full name(s):	Justin Peter Callahan
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Vice President - Sales & Marketing

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:	a) Options to acquire Ordinary Shares b) Performance Share Rights c) Ordinary Shares
Nature of the affected relevant interest(s):	Beneficial Interest

For that relevant interest-

Number held in class before acquisition or disposal:	a) 115,662 Options to acquire Ordinary Shares b) 94,597 Performance Share Rights c) 221,009 Ordinary Shares
Number held in class after acquisition or disposal:	a) 74,853 Options to acquire Ordinary Shares b) 76,839 Performance Share Rights c) 258,930 Ordinary Shares
Current registered holder(s):	Justin Peter Callahan
Registered holder(s) once transfers are registered:	Justin Peter Callahan

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:	
Class of underlying financial products:	

Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:	Two

Details of transactions requiring disclosure-

Date of transaction:	a) 16 September 2026 b) 16 September 2026
Nature of transaction:	a) Exercise and cancellation of Options and Issue of Ordinary Shares b) Exercise of Performance Share Rights and Issue of Ordinary Shares
Name of any other party or parties to the transaction (if known):	
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	a) Exercise price of $21.96 per Ordinary Share b) Nil
Number of financial products to which the transaction related:	a) Exercise of 40,809 Options and Issue of 20,163 Ordinary Shares b) Exercise of 17,758 Performance Share Rights and Issue of 17,758 Ordinary Shares

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period:	
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:	
Nature of relevant interest:	

For that relevant interest,-

Number held in class:	
Current registered holder(s):	

For a derivative relevant interest,-

Type of derivative:	

Details of derivative,-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

Certification

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	

or

Signature of person authorised to sign on behalf of director or officer:	Raelene Leonard
Date of signature:	18 September 2026
Name and title of authorised person:	Raelene Leonard, General Counsel & Company Secretary

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:	18 September 2026
Date of last disclosure:	9 September 2026

Director or senior manager giving disclosure

Full name(s):	Lyndal Jane York
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Chief Financial Officer

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:	a) Options to acquire Ordinary Shares b) Performance Share Rights c) Ordinary Shares
Nature of the affected relevant interest(s):	Beneficial Interest

For that relevant interest-

Number held in class before acquisition or disposal:	a) 101,299 Options to acquire Ordinary Shares b) 109,223 Performance Share Rights c) 52,617 Ordinary Shares
Number held in class after acquisition or disposal:	a) 43,691 Options to acquire Ordinary Shares b) 84,154 Performance Share Rights c) 52,617 Ordinary Shares
Current registered holder(s):	a) Lyndal Jane York b) Lyndal Jane York c) Lyndal Jane York and Alexander Eric York
Registered holder(s) once transfers are registered:	a) Lyndal Jane York b) Lyndal Jane York c) Lyndal Jane York and Alexander Eric York

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:	
Class of underlying financial products:	

Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	

For that derivative,-

Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:	Three

Details of transactions requiring disclosure-

Date of transaction:	a) 14 September 2026 b) 14 September 2026 c) 16 September 2026
Nature of transaction:	a) Exercise and cancellation of Options and Issue of Ordinary Shares b) Exercise of Performance Share Rights and Issue of Ordinary Shares c) Sale of Ordinary Shares
Name of any other party or parties to the transaction (if known):	
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	a) Exercise price of $21.96 per Ordinary Share b) Nil c) $43.64 per Ordinary Share
Number of financial products to which the transaction related:	a) Exercise of 57,608 Options and Issue of 28,317 Ordinary Shares b) Exercise of 25,096 Performance Share Rights and Issue of 25,069 Ordinary Shares c) Sale of 53,386 Ordinary Shares

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period:	
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:	
Nature of relevant interest:	

For that relevant interest,-

Number held in class:	
Current registered holder(s):	

For a derivative relevant interest,-

Type of derivative:	

Details of derivative,-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

Certification

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	

or

Signature of person authorised to sign on behalf of director or officer:	Raelene Leonard
Date of signature:	18 September 2026
Name and title of authorised person:	Raelene Leonard, General Counsel & Company Secretary